Publications by authors named "Veronique Chaigneau"
Amantadine use in the French prospective NS-Park cohort.
J Neural Transm (Vienna)
July 2024
Article Synopsis
- The study aimed to evaluate the use of amantadine in patients with Parkinson's disease (PD) and its effectiveness in treating levodopa-induced dyskinesia (LIDs).
- It found that 12.6% of PD patients in the French NS-Park cohort were using amantadine, primarily younger patients with more severe symptoms and higher doses of levodopa.
- The results indicated that starting amantadine led to significant improvements in LIDs and motor fluctuations among new users compared to those who had never used the drug.
Introduction: Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's. The French clinical research network for PD (NS-Park) has created a national patient registry to i)report medical activity of Parkinson Expert Centers (PECs) to the Ministry of Health, ii)facilitate PD patients pre-screening for clinical trials, iii) provide a source for pharmaco-epidemiology studies.
Objective: Assess the French Parkinsonian population at a nation-wide level and discover new clinical characteristics.
Introduction: There is an unmet need to better control motor complications in Parkinson's disease (PD). Naftazone, which exhibits glutamate release inhibition properties, has shown antiparkinsonian and antidyskinetic activity in preclinical models of PD and in a clinical proof of concept study.
Methods: We conducted a double-blind randomized placebo-controlled cross-over trial in PD patients with motor fluctuations and dyskinesia testing naftazone 160 mg/day versus placebo for 14 days.